Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.

@article{Meur2001PlasmaLA,
  title={Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.},
  author={Yannick Le Meur and V Lorgeot and L Comte and Jeff Szelag and Jean-Claude Aldigier and Claude Leroux-Robert and Vincent Praloran},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2001},
  volume={38 3},
  pages={510-7}
}
N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is a physiological inhibitor of hematopoiesis that is maintained at stable levels in normal plasma. Its degradation in vivo and in vitro by angiotensin-converting enzyme (ACE) accounts for the high plasma concentrations of AcSDKP in patients treated with ACE inhibitors. Because ACE inhibitors can induce anemia in some patients, we measured plasma AcSDKP concentrations in 176 patients with chronic renal failure: 120 hemodialysis (HD) and 56… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…